Calcium Lactate Composition for Hif-1α-Targeted Cancer Cachexia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer cachexia, such as COX-2 inhibitors and TNF-α inhibitors, are ineffective and have significant side effects, necessitating a novel approach to ameliorate symptoms like decreased appetite, weight loss, muscle loss, and fatigue.
Innovation Solution
A composition containing calcium lactate is administered to treat cancer cachexia, targeting Hif-1α protein under hypoxic conditions to reduce its expression in cancer cells while sparing normal cells, thereby addressing cachexia symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX-2 inhibitors are used to treat cancer cachexia, then skeletal muscle loss is reduced, but side effects such as anemia, gastric ulcers, allergies, heart attacks, and strokes occur
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (COX-2 enzyme and prostaglandin production) responsible for cancer cachexia pathology, using selective COX-2 inhibitors that specifically block this pathway while sparing other physiological systems, thereby reducing side effects while maintaining therapeutic effectiveness
Solution Approach 2:
The patent uses prostaglandins as intermediary molecules in the causal chain between COX-2 activation and muscle loss, and employs COX-2 inhibitors to block this intermediary pathway, thereby treating the underlying mechanism rather than just symptoms while avoiding direct toxicity to multiple systems
2Reliability
If TNF-α inhibitors are used to treat cancer cachexia, then cancer cell expression is reduced, but side effects such as depression, heart failure, dyspnea, vomiting, rash, hypertension, and birth defects occur
Solution Approach 1:
The patent extracts and specifically targets the TNF-α inflammatory pathway that is overactivated in cancer cachexia, using selective TNF-α inhibitors that block this specific cytokine's harmful effects while preserving other immune functions, thereby reducing side effects while maintaining anticancer activity
Solution Approach 2:
The patent applies local quality by targeting TNF-α specifically in the tumor microenvironment and cachexia-related tissues where it is pathologically elevated, rather than systemically suppressing all immune responses, thereby achieving localized therapeutic effect with minimal systemic side effects
3Reliability
If conventional cancer cachexia treatments are used, then some therapeutic effects are achieved, but evidence for therapeutic effects is lacking and many side effects occur
Solution Approach 1:
The patent incorporates feedback mechanisms through clinical trials and pharmacological studies that measure both therapeutic outcomes and side effect profiles, using this data to optimize dosing regimens and patient selection criteria, thereby accumulating evidence for therapeutic effectiveness while minimizing adverse effects
Solution Approach 2:
The patent employs parameter changes by optimizing dosage, administration frequency, and treatment duration based on pharmacokinetic and pharmacodynamic data, thereby maximizing therapeutic benefit while staying within safety margins, and systematically accumulating evidence through controlled studies
Data Source
AI summary
The present invention relates to a composition for ameliorating or treating cachexia containing calcium lactate as an active ingredient, and a method for treating cancer cachexia in a subject, the method comprising a step of administering calcium lactate or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. The calcium lactate of the present invention acts as a Hif-1α inhibitor and exhibits an effect of suppressing body mass loss due to cancer, so that it can be used as a candidate substance for solving the problem of cancer cachexia and suggests a synergistic effect between a medical nutritional product focused on anorexia and malnutrition and a Hif-1α inhibitor.